Form 4: Ideaya Biosciences Director Acquires Stock Options

Malcolm Garret Hampton, a director of Ideaya Biosciences, acquired stock options for 16,200 shares at an exercise price of $36.55 on May 31, 2024.

Summary

• On May 31, 2024, Malcolm Garret Hampton, a director of Ideaya Biosciences, Inc., acquired stock options for 16,200 shares.
• The exercise price for these options is $36.55.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting, contingent upon continued service on the Board.
• The options expire on May 30, 2034.
• Hampton also has granted power of attorney to certain officers of Ideaya Biosciences to execute and file forms related to securities transactions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally viewed as a positive sign, indicating confidence in the company's future prospects. However, it's a routine transaction and doesn't necessarily imply a significant change in the company's outlook.

Positives

• The acquisition of stock options by a director may signal confidence in the company's future performance.

Future Outlook

There are no specific forward-looking statements in this document.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common practice in publicly traded companies to align management and shareholder interests.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the biotechnology industry, used to incentivize and align their interests with those of shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also grant stock options to their directors as part of their compensation packages.
• The vesting schedules and exercise prices are typically structured to encourage long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.

Key Dates